A switch in kappa opioid receptor signaling from inhibitory to excitatory induced by stress in a subset of cortically-projecting dopamine neurons

Elyssa B. Margolis[1][*]

[1]UCSF Weill Institute for Neurosciences, Neuroscience Graduate Program, Department of Neurology, University of California, San Francisco, CA, United States

*Corresponding Author

Email: Elyssa.Margolis@ucsf.edu

Abstract

The kappa opioid receptor (KOR) has shown potential as a therapeutic target for several
neuropsychiatric disorders including major depressive disorder, pain, and substance use
disorder. *In vivo* signaling of G protein coupled receptors like the KOR is generally thought to
change in magnitude but not sign in such behavior states. Here we investigated KOR
modulation of ventral tegmental area (VTA) neurons following an acute, behaviorally aversive
manipulation. We found this experience switches KOR signaling from inhibitory to excitatory in a
subset of VTA dopamine neurons. Brief corticotrophin releasing factor (CRF) exposure *ex vivo*
rapidly induces a similar switch in KOR signaling, specifically in dorsal medial prefrontal cortex
(dmPFC) projecting neurons, but not nucleus accumbens or basolateral amygdala projecting
neurons. These KOR mediated excitations depend on G protein activation, but where
somatodendritic VTA KORs activate a K^+ conductance to hyperpolarize dopamine neurons in
control conditions, depolarizations require hyperpolarization-activated cyclic nucleotide-gated
channel (HCN) function. One behavioral impact of this change is a loss of the aversiveness of
intra-VTA KOR activation, providing direct evidence that rapid changes in signaling coupling of
one GPCR can be triggered by activity at other GPCRs thus significantly altering behavioral
responses driven by neuromodulators.

Introduction

Activation of the KOR system mediates immediate processing of and long-lasting behavioral
changes in response to aversive stimuli. Pharmacological blockade or genetic inactivation of
KORs can decrease the acute aversiveness of stressors, including pain, and promote resilience
to the development of depressive-like behaviors including decreased food reward seeking,
decreased social interactions, and increased immobility in forced swim and social defeat
paradigms[1–4]. Therefore, KOR antagonism has been proposed as a therapeutic approach to
neuropsychiatric disorders with symptom profiles that include aversive emotional and anhedonic
states, such as anxiety and depression, and to mitigate stress induced relapse to drug use[5].

The opioid receptor family of GPCRs commonly signals via inhibitory $G\alpha i/o$ activation[6]. Agonists
at somatodendritic KORs hyperpolarize neurons in a variety of brain regions including the dorsal
raphe, nucleus raphe magnus, and ventral pallidum[7–9]. In the VTA, KOR activation inhibits a
subset of dopamine neurons through G protein-gated inwardly rectifying K^+ channel (GIRK)
activation while non-dopamine neurons show no response[10]. Behaviorally, KOR activation in the
VTA is aversive[11], and intra-VTA blockade of KORs prevents the aversiveness of systemic KOR
agonist administration[12]. Intra-VTA KOR blockade also prevents stress induced reinstatement of
cocaine seeking[13]. Paradoxically, aversive stress blunts some physiological KOR responses,
such as the KOR coupled GIRK conductance in serotonergic dorsal raphe neurons[8].
Understanding KOR function in relevant behavior states will improve our ability to treat the
target neuropsychiatric disorders.

Here we investigated postsynaptic KOR agonist responses in VTA neurons after an acute
aversive stressor in order to improve our understanding of what functionality KOR antagonism
might have in a therapeutically relevant state. Rather than a change in response magnitude,
acute aversive stress caused a change in the sign of the physiological response to KOR
activation in a subset of VTA neurons. Importantly, this change was specific to VTA dopamine
neurons projecting to the dmPFC, a site where dopamine function contributes to executive
function and reward processing[14–17].

Results

We performed *ex vivo* whole cell recordings in rat VTA neurons after a single session of
aversive foot shock stress, making slices 30-60 min after the stressor. All statistics are
described in Table 1. In addition to VTA neurons that responded to the KOR selective agonist
U69,593 (1 μM) with a hyperpolarization or no change in membrane potential similar to prior
observations in untreated animals[10,18,19], we unexpectedly observed depolarizations in a distinct
subset of neurons from both male and female rats (Fig. 1a-d). This includes neurons confirmed
as dopaminergic with immunocytochemistry (Fig. 1b, Extended Data Fig. 1a; recording locations
in Extended Data Fig. 1b). Depolarizations were still observed 3 (4/18 neurons), but not 5 (0/7
neurons), days after the foot shock stress session (Fig 1d). Action potential (AP) threshold was
more depolarized in neurons from foot shock stressed rats compared to shams, but the stressor
did not alter other basal properties of VTA neurons including baseline input resistance (Ri), AP
duration, AP peak, h current magnitude, or spontaneous firing rate (Extended Data Fig. 2). In
the recordings from stressed animals, initial Ri was greater in neurons that subsequently
showed a depolarization in response to U69,593 compared to neurons that subsequently
showed a hyperpolarization (Extended Data Fig. 3). No other differences were detected in
baseline physiological properties across VTA neurons grouped by their U69,593 responses
(Extended Data Fig. 3). One possibility is that the aversive stressor decreases GIRK function in
a subset of neurons, unmasking the observed depolarizing effect of U69,593. However, when
we blocked GIRKs in slices from control, untreated animals with $BaCl_2$ (100 μM), the distribution
of responses to U69,593 was clearly different from those from stressed animals with no
depolarization > 0.8 mV (Fig. 1d,e). Dopamine D2 receptor activation hyperpolarizes a subset of
VTA neurons through GIRK channel activation[20]. If acute, aversive stress decreases GIRK
function in VTA neurons rather than change KOR signaling, we would expect to observe a shift
in responses to the D2R agonist quinpirole (1 μM) as well. The means and distributions of
quinpirole responses were not different between VTA neurons from sham and foot shocked rats
(Fig. 1f).

Figure 1. Following a single foot shock session, a subset of VTA neurons depolarize in
response to KOR activation. *(a) Rats experienced a single intermittent foot shock session (10*
min) prior to ex vivo whole cell recordings. (b) Example recording from a VTA neuron (biocytin
fill: red) that was confirmed as dopaminergic with TH immunocytochemistry (green), scale bar
10 μm. In whole cell current clamp configuration (I = 0 pA) bath application of the KOR agonist
U69,592 (1 μM) caused a depolarization. Inset: I_h measured in voltage clamp, scale bars 200 pA
and 200 ms. (c) Mean time course of responses in neurons that were significantly depolarized

The corticotrophin releasing factor (CRF) system is upstream of the KOR system in encoding
the aversiveness of stressful experiences[21], and blocking KORs can prevent CRF-induced
anxiety-like behaviors[22,23]. As foot shock stress drives CRF release in the VTA[24], we tested the
hypothesis that incubating VTA slices from control animals with no behavioral manipulations in
CRF would produce similar changes in KOR signaling to the *in vivo* aversive stressor exposure.
In fact, in VTA slices incubated in 200 nM CRF for 5 min, a subset of neurons responded to
subsequent U69,593 application with a depolarization (Fig. 2a). Next we tested whether
neurons excited by KOR activation after CRF were the same neurons inhibited by KOR
activation under control conditions or a previously KOR-insensitive population. All neurons that
showed a depolarization in response to KOR activation after CRF showed a hyperpolarization to
KOR activation before CRF (Fig. 2b,c). In fact, for neurons that showed a depolarization after
CRF, there was a clear inverse correlation (n = 5 neurons; coeff. = -0.9) between the
magnitudes of KOR responses before and after CRF application (Fig. 2c).

Figure 2. ex vivo exposure to CRF can switch KOR signaling from inhibitory to excitatory. *(a) Summarized data, each circle is a neuron. Slices were incubated for 5 min with CRF (200 nM), CRF was washed out for at least 5 min, then U69,593 (1 μM) was bath applied for 5 min. Statistical comparison to U69,593 responses in VTA neurons from naïve rats (Fig. 1e left), Permutation analysis of means, p = 0.00004. (b) Left, U69,593 (1 μM) was applied once, washed out, then reapplied (paired t-test p = 1.0). Right, U69,593 (1 μM) was applied once, washed out, CRF was washed on (5 min, 200 nM), washed out, then U69,593 was reapplied (paired t-test p = 0.08). (c) Data from (b) graphed as magnitude of response to first U69,593 application to second application.*

We previously reported that VTA dopamine neurons that project to the mPFC and basolateral
amygdala (BLA), but not the nucleus accumbens (NAc), are inhibited by somatodendritic KOR
activation in rat[18,19]. To test whether the signaling switch happens in a projection selective
manner, we recorded from retrogradely labeled VTA neurons that project to dmPFC (including
prelimbic and anterior cingulate cortices), ventral mPFC (infralimbic cortex), medial NAc, and
BLA blind to injection site. Most distinctly, dmPFC-projecting VTA neurons showed the strongest
depolarizations after CRF exposure while none of the vmPFC-projecting neurons depolarized
(Fig. 3). NAc- and BLA-projecting showed no and minimal depolarizations, respectively (Fig. 3).
Thus, the switch in KOR signaling from inhibitory to excitatory occurs in a specific subpopulation
of dmPFC-projecting VTA neurons.

Figure 3. CRF switches KOR signaling in a subpopulation of dmPFC-projecting VTA neurons. U69,593 responses were recorded in retrogradely labeled neurons after slices were incubated in CRF (5 min, 200 nM). Kruskal-Wallis rank sum test p = 0.006, pairwise comparisons listed in Table 1.

Next we probed the signaling mechanism underlying the KOR mediated excitations triggered by
CRF exposure. To test whether the KOR excitations are due to indirect effects involving local
connectivity in the slice we measured KOR agonist responses while blocking AMPARs (10 μM
DNQX), GABA$_A$Rs (20 μM gabazine), and action potential activity (500 nM TTX). This did not
prevent U69,593 induced depolarizations (Fig. 4a). To block G protein signaling in the recorded
neuron we included GDP-β-s in the intracellular solution (500 μM), and broke in to whole cell
configuration only after CRF application was completed. This G protein block eliminated both
depolarizations and hyperpolarizations induced by U69,593 (Fig. 4a). Together these data show
that the KOR induced depolarizations are not local circuit dependent, and because the G protein
blockade was limited to the recorded neuron the KORs in question appear to be expressed in
the recorded neuron. GPCR activation could cause depolarization by closing GIRKs[25], however
blocking GIRKs with BaCl$_2$ (100 μM) did not prevent U69,593 induced depolarizations (Fig. 4a).
We previously reported that mu and delta opioid receptors (MORs and DORs) on VTA neurons
can drive depolarizations that require Ca^{2+} channel conductances[26,27], however in the present
study, blocking Ca^{2+} channels with bath application of CdCl$_2$ (100 μM) did not prevent U69,593
induced depolarizations (Fig. 4a). A Na$^+$ leak current contributes to the maintenance of a
depolarized potential and spontaneous AP firing in VTA neurons[28,29] that can be inhibited by
Gαi/o protein coupled receptors[30]. Blocking this conductance did not prevent U69,593 induced
depolarizations (Fig. 4a).

Figure 4. KOR mediated depolarizations require I_h. (a) Signaling mechanism(s) that
contribute to U69,593 (1 μM) induced depolarizations were investigated after exposing slices ex
vivo to CRF (5 min, 200 nM). TTX (500 nM), DNQX (10 μM), and gabazine (20 μM) blocked
synaptic transmission; intracellular GDP-β-s (500 μM) blocked intracellular G protein signaling;
ZD7288 (10 μM) blocked HCN channels (I_h); BaCl$_2$ (100 μM) blocked K$^+$ channels; CdCl$_2$ (100
μM) blocked Ca^{2+} channels; replacement of Na$^+$ with NMDG (151 mM, replacing NaCl) in aCSF
blocked Na$^+$ leak current; SB203580 (10 μM) blocked p38/MAPK signaling. (b) I_h magnitude
was measured during U69,593 (1 μM) application in voltage clamp, stepping from -60 mV to -
120 mV, in control slices or slices pretreated with CRF (5 min, 200 nM). (c) p38/MAPK was
blocked with SB203580 application during both CRF and U69,593 application.

I_h is a hyperpolarization activated, non-selective cation conductance that we found is prominent
in mPFC-projecting VTA neurons[19]. In nodose ganglion neurons MOR activation inhibits I_h[31],
and in the nucleus raphe magnus (NRM) KOR activation augments I_h[32]. The I_h blocker ZD7288
prevented U69,593 induced depolarizations (Fig. 4a). Given that the reversal potential for I_h is
depolarized compared to typical membrane potentials, the simplest possibility is that KOR
activation augments I_h conductance. Consistent with this, we found that U69,593 increased I_h
amplitude in a subset of neurons recorded in slices pretreated with CRF, and this response that
was not observed in control slices (Fig. 4b). CRF pretreatment did not impact other I_h properties
measured during U69,593 application (Extended Data Fig. 4).

Bruchas and colleagues reported that P38 MAPK contributes to some KOR mediated behavioral
changes following aversive stressors *in vivo*[33]. Here we tested for a contribution of p38 to this
KOR switch or KOR signaling. Incubating slices from control rats with the p38 blocker
SB203580 prior to CRF application prevented subsequent U69,593 induced depolarizations
(Fig. 4c). However, when slices were exposed to CRF prior to incubation in SB203580, U69,593
induced depolarizations persisted (Fig. 4a). We conclude that CRF receptor activation alters the
signaling of a subset of KORs in the VTA through a p38 dependent signaling pathway, but
KORs are not signaling through p38 directly to depolarize neurons.

Finally, we tested for a behavioral consequence of this change in KOR signaling. Decreases in
dopamine neuron activity canonically encode punishment and aversion, and therefore intra-VTA
KOR agonist induced aversion is widely thought to be due to inhibition of dopamine neurons. In
the context of this model, a switch in KOR signaling in dopamine neurons from inhibitory to
excitatory would be predicted to diminish conditioned place aversion (CPA) to intra-VTA KOR
agonist microinjection. Since we found the switch in signaling sign to last between 3 and 5 days,
we designed a paradigm where the animals received foot shock on days 1 and 6 in order to
maintain stress-induced changes to KOR signaling. Pairings of either intra-VTA U69,593 (0.2
mM, 0.5 mL/side) or vehicle once per day were performed on non-stress days, for a total of four
pairings per side (Fig. 5a), in order to minimize the formation of a direct association between the

foot shock stress and the place preference manipulation. Indeed, foot shock stress pretreatment eliminated the development of CPA to intra-VTA U69,593 (Fig. 5b, placements in Extended Data Fig. 5).

Figure 5. Foot shock stress eliminates intra-VTA KOR mediated aversion. *(a) Experiment timeline where rats were trained in a conditioned place preference paradigm, to intra-VTA U69,593 (0.2 mM, 0.5 mL/side) or vehicle. Rats were pretreated with sham handling or foot shock stress on non-pairing days. (b) Baseline vs post training test for place conditioning. Two way mixed measures ANOVA) Pairwise comparisons: Sham, baseline vs post test: 0.0004 Shock, baseline vs post test: 0.6 (Bonferroni corrected).*

Discussion

163
Together these data show that a single stressful event can dramatically change the signaling
sign of a modulatory GPCR system. The change occurs in a specific neural circuit and can
persist for days. This stress induced switch at KORs can be induced by the stress-associated
CRF neuropeptide-GPCR system in the same brain region, and while the signaling is still G
protein mediated, it appears that the key conductance involved is I_h, a switch from GIRK
coupling.

The contributions of VTA dopamine neurons to the processing of aversive experiences
encompass motivational and learning components and are circuit-specific[34]. *In vivo*
electrophysiology studies show that while many midbrain putative and opto-tagged dopamine
neurons decrease their firing when a predicted reward is omitted (i.e., an aversive outcome)[34,35],
some putative and directly identified dopamine neurons increase their firing in response to an
aversive sensory stimulus[36,37]. We previously demonstrated that in control rats, KOR activation
inhibits VTA dopamine neurons that project to the mPFC and BLA, but not the NAc[18,19]. With
microdialysis, we confirmed that *in vivo* VTA KOR activation decreases dopamine release in
mPFC but not in the NAc[19]. Here we show a switch from inhibitory to excitatory signaling in a
subpopulation of dmPFC-projecting VTA neurons after CRF exposure. This excitatory KOR
effect may contribute to the reported stress induced activation of dmPFC-projecting VTA
dopamine neurons[35,36]. The loss of intra-VTA KOR agonist induced CPA after the stress
induced switch in KOR signaling also implicates the dopaminergic projection to dmPFC in value
signaling. Consistent with this, MOR activation in the VTA causes an increase in dopamine
release in the anterior cingulate cortex (ACC, included in the dmPFC in this study), and
lesioning dopamine terminals there decreases the magnitude of intra-VTA MOR agonist induced
conditioned place preference[15]. Also, genetic deletion of KOR from TH neurons and stress
induced augmentation of cocaine CPP[37]. The transfer function of dopamine activity in the mPFC
has been extensively studied, but a synthesized understanding of its contributions to mPFC
processing of value remains somewhat elusive[38–40].

Here we discovered a convergence of two neuropeptide systems, with CRF changing the sign
of the physiological response of KORs in a specific neural circuit. There are at least a dozen

possible sources of CRF to the VTA including the bed nucleus of the stria terminalis, dorsal
raphe, parabrachial nucleus, lateral dorsal tegmentum, and local VTA neurons[41,42] any of which
might be activated by aversive stressors. A subset of VTA neurons express CRF receptor 1
(CRF-R1) and the CRF binding protein, but not CRF receptor 2[43,44]. Blocking CRF-R1 in the
VTA decreases foot shock stress induced reinstatement of cocaine seeking[35]. Intra-VTA KOR
blockade[13] and intra-dmPFC dopamine antagonists also mitigate stress induced reinstatement
of cocaine seeking[35,45], a provocative parallel to the neuromodulatory circuit identified here.

We found that blocking I_h prevented KOR agonist induced depolarizations. Even though I_h is
generated by hyperpolarization activated, cyclic nucleotide-gated (HCN) channels[46,47] and thus
opioid receptors might interact with them though cAMP modulation, in the NRM KOR activation
in tissue from control rats augments I_h through a cAMP-independent signaling pathway that
involves intracellular release of Ca^{2+} [32]. In these neurons, cAMP activation causes a positive
shift in the voltage dependence of I_h, but does not change the maximum I_h amplitude. In the
VTA, the adenylyl cyclase activator forskolin causes a shift in the I_h $V_{1/2}$ to a more depolarized
potential[48]. The isoform HCN3, which is expressed in the vast majority of VTA dopamine
neurons and in many more VTA neurons than isoforms 1, 2 or 4[48], is relatively insensitive to
cAMP[46,49]. Here, KOR activation after CRF did not alter I_h $V_{1/2}$, consistent with a cAMP-
independent effect.

An increase in HCN channel function in the VTA has been implicated in behavioral changes
induced by aversive stressors. For instance, after social defeat stress in mice, I_h magnitude is
larger in VTA neurons of susceptible mice compared to those of control mice[50]. Blocking I_h in the
VTA[50,51] and systemically[52] reverse the social avoidance induced by social defeat. Our data
suggest that *in vivo* activity at KORs in the VTA after stress increases I_h function in dmPFC-
projecting dopamine neurons. Thus decreasing I_h function in the VTA may be one common
therapeutic target, be it through direct HCN blockade or KOR antagonism.

What are the *in vivo* consequences of this switch in KOR signaling? At the circuit level, this
switch means that the change in VTA dmPFC-projecting dopamine neuron firing will have an
opposite sign when an endogenous KOR ligand is released into the VTA. That is, the
peptidergic inputs to the VTA may have the same behavior-related firing patterns as before an
aversive stressor, but the impact on dmPFC dopamine release will be the inverse. In addition to
contributing to value encoding, dopamine function in the dmPFC also contributes to executive
function[16,17]. For instance, dopamine lesions in in the ACC impairs attentional set shifting[41] and
dopamine receptor antagonists delivered to the prelimbic cortex degrade decision making[42].
These and other studies suggest that ongoing or increases in dopamine release in the dmPFC
contribute to saliency processing, and support working memory[43], which are particularly
advantageous to engage following an aversive stressor. Following chronic stress that induces
anhedonia, activating mPFC-projecting VTA dopamine neurons reverses immobility and loss of
sucrose preference[44], and an increase in dopamine signaling in dmPFC also relieves ongoing
pain[45]. Provocatively, stress induced analgesia is also blocked by systemic administration of the
KOR selective antagonist norBNI[46], which in the context of our results would prevent an
increase in dopamine release in the dmPFC, although it is not yet known if dmPFC-projecting
VTA dopamine neurons contribute to this phenomenon. Together, these studies raise the
possibility that this switch in VTA KOR function is adaptive, with an optimal concentration of
dopamine in the mPFC facilitating learning. Learning about acutely aversive experiences, and
how to avoid them, is critical to survival.

Methods

Animals.

All experiments were performed in accordance with the guidelines of the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and the Institutional Animal Care and
Use Committees (IACUC) at the University of California San Francisco. Male and female
Sprague Dawley rats (p35 – p120 for electrophysiology; > 250g for behavior) were obtained
from Inotiv or Charles River Laboratories. Rats were allowed access to food and water ad
libitum and maintained on a reverse 12 h:12 h light/dark cycle. Rats were group housed except
those with cannula implants.
246
Foot shock stress.
Operant chambers equipped with a foot shock grid were used for administering aversive
stressors (physical boxes manufactured by Med. Associates with custom updated electronics
controlled by microcontroller (Arduino)). Foot shock or sham sessions were 10 min, delivering
10, 0.8 mA intensity, 0.5 s duration shocks. Intervals between shocks were randomized (10 –
110 sec) in order to avoid predictability. Foot shock stress moderately elevated blood CORT,
samples taken directly after foot shock session (Extended Data Fig. 6).
254
Electrophysiology.
Rats were deeply anesthetized with isoflurane, decapitated, and brains were quickly removed
and cooled with ice-cold artificial cerebrospinal fluid (aCSF) consisting of (in mM): 119 NaCl, 2.5
KCl, 1.0 NaH_2PO_4, 26.2 $NaHCO_3$, 11 glucose, 1.3 $MgSO_4$, 2.5 $CaCl_2$, saturated with 95% O_2-5%
CO_2, with a measured osmolarity 310–320 mOsm/L. Horizontal sections (150 μm) containing
the VTA were cut with a Leica VT 1000 S or a Campden 7000smz-2 vibratome. Tissue
containing the DiI injection sites was drop fixed in 4% formaldehyde to confirm targeting, with
recordings in DiI labeled neurons made blind to injection target. Slices were incubated in
oxygenated aCSF at 33 °C and allowed to recover for at least one hour. A single slice was
placed in the recording chamber and continuously superfused with oxygenated aCSF (2
mL/min). Neurons were visualized with an upright microscope (Zeiss AxioExaminer.D1)
equipped with infrared-differential interference contrast, Dodt optics, and fluorescent
illumination. Whole-cell recordings were made at 34 °C using borosilicate
glass microelectrodes (3–5 MΩ) filled with K-gluconate internal solution containing (in mM): 123
K-gluconate, 10 HEPES, 8 NaCl, 0.2 EGTA, 2 MgATP, 0.3 Na_3GTP, and 0.1% biocytin (pH 7.2
adjusted with KOH; 275 mOsm/L). Liquid junction potentials were not corrected. Input
resistance was monitored throughout voltage clamp experiments with a −4 mV step
every 30 s.
Signals were recorded using an Axopatch 1D (Molecular Devices, San Jose, CA) or IPA (Sutter
Instruments, Novato, CA). Signals were filtered at 5 kHz and collected at 20 kHz using IGOR
Pro (Wavemetrics) and custom data acquisition routines or collected at 10 kHz using
SutterPatch software (Sutter Instruments).
Baseline hyperpolarization-activated cation currents (I_h) were recorded in each neuron by
voltage clamping cells at -60 and stepping to -40, -50, -70, -80, -90, -100, -110, and -120 mV.
Recordings were then made in current clamp mode (I = 0 pA). Changes in I_h properties were
measured in voltage clamp, alternating between two step series (Extended Data Fig. 4) with one
series commencing each 2.17 min.
After recordings, slices were drop fixed in 4% PFA for at least 2 h at 4 °C and processed
for tyrosine hydroxylase (TH) immunocytochemistry and biocytin labeling. Recording were made
from throughout the VTA.
285
Immunocytochemistry.
Slices were preblocked for 2 h at room temperature in PBS with 0.3% Tween20 and 5% normal
goat serum, then incubated at 4°C with a rabbit anti-TH polyclonal antibody (1:400; EMD
Millipore, RRID: AB_390204). Slices were then washed thoroughly in PBS with 0.3% Tween20

before being agitated overnight at 4°C with Cy5 anti-rabbit secondary antibody (1:1000; Jackson
ImmunoResearch, RRID: AB_2534032) and FITC streptavidin (1:200; Jackson
ImmunoResearch, AB_2337236). Tween20 was excluded in slices with DiI. Sections were
rinsed and mounted on slides using VECTASHIELD® Antifade Mounting Media (Vector
Laboratories) and visualized with an Axioskop FS2 Plus (Zeiss) with an Axiocam MRm (Zeiss)
running Neurolucida (MBF Biosciences).
296
CORT ELISA.
Tail vein blood samples were collected immediately after foot shock or sham sessions from
behavior animals. Trunk blood was collected at time of slice preparation for electrophysiology
animals. Samples were centrifuged, then serum was frozen and stored at -80°C. ELISA kits
were used as directed (DetectX Corticosterone Enzyme Immunoassay Kit (product # K014-H1);
Arbor Assays).
303
304 **Stereotaxic surgeries.**
305 *Tracer injections.* Rats weighing 275–300 g were anesthetized with 3–5% isoflurane (Henry
306 Schein) via inhalation and secured in a stereotaxic frame. Bilateral craniotomies were created
307 with a dental drill above the injection site.
308
Tracer injections. Bilateral injections of DiI (7% in ethanol; Biotium, Hayward, CA) were made in
the dmPFC (2.0 mm AP, ± 0.6 mm ML, -2.8 mm V), vmPFC (2.0 mm AP, ± 0.6 mm ML, -4.8
mm V), NAc (1.2 mm AP, ± 0.8 mm ML, -7.4 mm V), or basolateral amygdala (-3.3 mm AP, ±
5.0 mm ML, -8.4 mm V) using a Nanoject II (Drummond Scientific, Broomall, PA). 50 – 300 nL
was injected in each hemisphere over ~5 min. The injector tip was left in place for at least 2
minutes after injection to decrease backflow and spread to tissue dorsal to the injection site.
Recordings were made 7-8 days later.
316
317 *Cannulation.* For microinjections into the VTA, bilateral guide cannulae were implanted 1 mm
318 above the VTA (−5.8 mm AP, ±0.5 mm ML,−7.2 mm DV). A dummy stylet was inserted to
319 maintain patency of the cannulae. Cannulae were anchored with flat point screws and dental
320 cement.
321
322 *Analgesia and recovery.* Rats were treated with subcutaneous Carprofen (5 mg/kg, Zoetis) and
323 topical 2% lidocaine (Phoenix Pharmaceutical, Inc.) during the surgery for pain control. After
324 surgery, animals had access to liquid Tylenol (~1:40) in their drinking water for 3–5 days or
325 were administered Meloxicam (s.c. 2 mg/kg, Pivetal) once per day for two days. All DiI and
326 cannulae placements were histologically verified postmortem.
327
Conditioned place preference.
Rats were allowed to recover for 1–2 weeks prior to behavioral testing. First, all rats were tested
for bias in the conditioning boxes. The conditioning boxes (physical boxes purchased from Med.
Associates, Georgia, VT, USA with custom updated electronics (Arduino; IR beam breaks
(Adafruit)) and software have three divisions: two conditioning chambers (25 cm × 21 cm × 21
cm) with distinct visual (horizontal vs. vertical stripes) and textural (thick vs. thin mesh flooring)
cues, separated by a smaller gray neutral chamber (12 cm × 21 cm × 21 cm). Animals were
allowed up to three opportunities to show neutrality across the chambers during 20-min baseline
sessions. Rats that displayed a consistent baseline preference (>65% of time spent in one
chamber) were excluded from the study. Rats were pseudorandomly assigned to receive
U69,593 in one of the conditioning chambers, and assignments were counter-balanced for each
cohort.

The paradigm commenced with a foot shock or sham treatment as described above, completed
in a different room from the conditioning chambers. Starting the next day, conditioning pairings
(20 min) occurred once daily for 4 consecutive days alternating U69,593 (0.2 mM) and vehicle
(0.5 mL/side). This 5 day series (including foot shock/sham) was repeated a second time for a
total of 4 pairings for U69,593 and vehicle, each. Finally, on test day, rats were drug free and
had access to all three chambers for 20 min. Difference score was defined as (Time
spent in U69,593 paired chamber)−(Time spent in vehicle paired chamber).
347
348 *Microinjections*. Rats were lightly restrained in a cloth wrap for intracranial microinjections. A
349 bilateral 33 G microinjector (PlasticsOne) that extended 1 mm ventrally beyond the guide
350 cannula was inserted to deliver drug. Hamilton syringes were driven by a dual syringe pump to
351 deliver the injection volume over 2 min. Injectors were left in place for 1 min after injection.
352
Brain removal and histochemistry. To check cannulae placements, rats were deeply
anesthetized with an intraperitoneal injection of Euthasol (0.1 mg/kg, Virbac Animal Health) after
0.3 µL of Chicago Sky Blue (in 2% PBS) was injected through the cannulae to mark injection
locations. After becoming unresponsive to noxious stimuli, the rats were transcardially perfused
with 400 mL of saline, followed by 400 mL of 4% paraformaldehyde (PFA) in 0.1 M phosphate
buffer. The brains were extracted and immersion-fixed in PFA for 2 h at room temperature (RT),
washed two times with PBS to remove excess PFA, and stored in 1X PBS at 4°C.
Perfused brains and drop fixed DiI containing tissue were sectioned (50 µm) using a vibratome
(Leica VT 1000S). Alternating slices were Nissl stained. Sections were mounted on slides using
VECTASHIELD® mounting medium (Vector Laboratories). Microinjection locations for rats
included in the behavior study are summarized in Extended Data Fig. 5.
364
Data analysis.
The magnitude of U69,593 induced changes in V_m were quantified by comparing the mean
values over the last 4 min of U69,593 application to the 4 minutes of baseline just prior to
starting the drug application. Responses were tested for significance by statistically comparing
30 sec bins during these two time periods (unpaired Student's t-test). I_h magnitude was
measured as the difference between the initial capacitive response to a voltage step from −60 to
−120 mV and the final current during the same step. Reported baseline Ri and firing rate are the
average measurements over the first 2 min of I_{clamp} recording. For AP duration measurements,
at least 8 waveforms were averaged together and duration was calculated from threshold on the
ascending phase to recrossing threshold on the falling phase. Threshold was identified as the
first datapoint where the derivative of the waveform exceeds 10 V/s. For evaluation of KOR
agonist induced changes in I_h properties, see measurements described in Extended Data Fig. 4.
377
378 Population statistics were performed in R. Where datasets failed tests of normality or
379 homogeneity of variance, non-parametric permutation analyses (https://github.com/eb-margolis-
380 neuroscience-lab/R-general-Margolislab/tree/main) were used to test for statistical significance.
381 For behavior data, mixed measures two-way ANOVA was used with Bonferroni correction for
382 multiple comparisons.
383

Acknowledgements
I thank Joseph R. Driscoll, Thomas J. Cirino, Peter Fong, Aashka Popat, Ben J. Ngu, Benjamin
Snyder, Kasra Mansorian, and Madelyn Moulton for technical assistance. This work was
supported by National Institutes of Health grants R01DA030529, R01DA042025 and
R01DA008863, and funds from the State of California for medical research on alcohol and
substance use.

Figure Captions

Figure 1. Following a single foot shock session, a subset of VTA neurons depolarize in response to KOR activation. (a) Rats experienced a single intermittent foot shock session (10 min) prior to *ex vivo* whole cell recordings. (b) Example recording from a VTA neuron (biocytin fill: red) that was confirmed as dopaminergic with TH immunocytochemistry (green), scale bar 10 μm. In whole cell current clamp configuration (I = 0 pA) bath application of the KOR agonist U69,592 (1 μM) caused a depolarization. Inset: I_h measured in voltage clamp, scale bars 200 pA and 200 ms. (c) Mean time course of responses in neurons that were significantly depolarized by U69,593. (d) Summarized data, each circle is a neuron, from same day sham shock, same day shock, 3 days after shock and 5 days after shock treated rats. Circles and triangles indicate VTA neurons from male and female rats, respectively. Permutation analysis comparing means of U69,593 responses in sham vs shock, p = 0.02 (Table 1) (e) Summarized U69,593 responses in VTA neurons from naïve rats, and from naïve rats where U69,593 responses were measured in BaCl$_2$ (100 μM). Statistical comparison performed was permutation analysis comparing variances (SDs; $ indicates p<0.05), p = 0.04. (f) Summarized responses to the dopamine D2 receptor agonist quinpirole (1 μM) in VTA neurons from naïve, sham, and foot shocked rats. One way ANOVA sham vs shock, p = 0.9.

Figure 2. *ex vivo* exposure to CRF can switch KOR signaling from inhibitory to excitatory. (a) Summarized data, each circle is a neuron. Slices were incubated for 5 min with CRF (200 nM), CRF was washed out for at least 5 min, then U69,593 (1 μM) was bath applied for 5 min. Statistical comparison to U69,593 responses in VTA neurons from naïve rats (Fig. 1e left), Permutation analysis of means, p = 0.00004. (b) Left, U69,593 (1 μM) was applied once, washed out, then reapplied (paired t-test p = 1.0). Right, U69,593 (1 μM) was applied once, washed out, CRF was washed on (5 min, 200 nM), washed out, then U69,593 was reapplied (paired t-test p = 0.08). (c) Data from (b) graphed as magnitude of response to first U69,593 application to second application.

Figure 3. CRF switches KOR signaling in a subpopulation of dmPFC-projecting VTA neurons. U69,593 responses were recorded in retrogradely labeled neurons after slices were incubated in CRF (5 min, 200 nM). Kruskal-Wallis rank sum test p = 0.006, pairwise comparisons listed in Table 1.

Figure 4. KOR mediated depolarizations require I_h. (a) Signaling mechanism(s) that contribute to U69,593 (1 μM) induced depolarizations were investigated after exposing slices *ex vivo* to CRF (5 min, 200 nM). TTX (500 nM), DNQX (10 μM), and gabazine (20 μM) blocked synaptic transmission; intracellular GDP-β-s (500 μM) blocked intracellular G protein signaling; ZD7288 (10 μM) blocked HCN channels (I_h); BaCl$_2$ (100 μM) blocked K$^+$ channels; CdCl$_2$ (100 μM) blocked Ca^{2+} channels; replacement of Na$^+$ with NMDG (151 mM, replacing NaCl) in aCSF blocked Na$^+$ leak current; SB203580 (10 μM) blocked p38/MAPK signaling. (b) I_h magnitude was measured during U69,593 (1 μM) application in voltage clamp, stepping from -60 mV to -120 mV, in control slices or slices pretreated with CRF (5 min, 200 nM). (c) p38/MAPK was blocked with SB203580 application during both CRF and U69,593 application.

Figure 5. Foot shock stress eliminates intra-VTA KOR mediated aversion. (a) Experiment timeline where rats were trained in a conditioned place preference paradigm, to intra-VTA U69,593 (0.2 mM, 0.5 mL/side) or vehicle. Rats were pretreated with sham handling or foot shock stress on non-pairing days. (b) Baseline vs post training test for place conditioning. Two way mixed measures ANOVA) Pairwise comparisons: Sham, baseline vs post test: 0.0004 Shock, baseline vs post test: 0.6 (Bonferroni corrected).

Extended Data Figure 1. (a) Summary of responses to U69,593 in neurons identified at TH(+) with immunocytochemistry. These are a subset of the data in Fig. 1d. (b) Locations of VTA neurons recorded from same day foot shock stress rats. Color indicates change in Vm in response to U69,593.

Extended Data Figure 2. Physiological properties recorded in VTA neurons from foot shock (same day) or sham rats. Quantifications of data collected during the first 150 s immediately after whole cell access is achieved. (a) Ri, (b) AP duration, (c) AP threshold, (d) AP peak, (e) I_h magnitude (f) spontaneous firing rate. $**p < 0.01$

Extended Data Figure 3. Foot shock rat data from Supplementary Figure 2, sorted by the type of response to U69,593. (a) Ri, (b) AP duration, (c) AP threshold, (d) AP peak, (e) I_h magnitude $*p < 0.05$

Extended Data Figure 4. I_h measurements. (a) top, schematic of V step commands from V=-40 mV to quantify $V_{1/2}$ and activation τ. Bottom, example response. (b) top, schematic of V step commands from V = -40 mV to quantify reversal V. Bottom, example response from the same neuron as in (a). (c) Example single exponential fit to data in (a). (d) Schematic of experiment design. Step series shown in (a) and (b) were applied to each neuron for a "baseline" measurement and again during U69,593 application. (e) Difference between $V_{1/2}$ measured at baseline and in U69,593. Grey is no pretreatment, Orange is CRF pretreatment. (f) Difference between $V_{reverse}$ measured at baseline and in U69,593. Grey is no pretreatment, Orange is CRF pretreatment. (g) I_h activation τ at baseline vs in U69,593. Grey is no pretreatment, Orange is CRF pretreatment.

Extended Data Figure 5. Microinjection sites for intra-VTA place conditioning experiments in Figure 5.

Extended Data Figure 6. CORT measured (ELISA) from trunk blood samples collected from same day foot shock and sham animals during brain slice preparation. $* p = 0.05$

References

1. Varlinskaya, E. I., Spear, L. P. & Diaz, M. R. Stress alters social behavior and sensitivity to pharmacological activation of kappa opioid receptors in an age-specific manner in Sprague Dawley rats. *Neurobiol. Stress* **9**, 124–132 (2018).

2. McLaughlin, J. P., Li, S., Valdez, J., Chavkin, T. A. & Chavkin, C. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. *Neuropsychopharmacology* **31**, 1241–8 (2006).

3.   Massaly, N. *et al.* Pain-Induced Negative Affect Is Mediated via Recruitment of The

Nucleus Accumbens Kappa Opioid System. *Neuron* (2019)

doi:10.1016/j.neuron.2019.02.029.

4.   Groblewski, P. A., Zietz, C., Willuhn, I., Phillips, P. E. M. & Chavkin, C. Repeated stress

exposure causes strain-dependent shifts in the behavioral economics of cocaine in rats.

Addict. Biol. **20**, 297–301 (2015).

5.   Carlezon Jr., W. A. & Krystal, A. D. Kappa-Opioid Antagonists for Psychiatric Disorders:

From Bench to Clinical Trials. *Depress. Anxiety* **33**, 895–906 (2016).

6.   Reeves, K. C., Shah, N., Muñoz, B. & Atwood, B. K. Opioid Receptor-Mediated Regulation

of Neurotransmission in the Brain. *Front. Mol. Neurosci.* **15**, 919773 (2022).

7.   Ji, M. *et al.* Dynorphin promotes stress-induced depressive behaviors by inhibiting

ventral pallidal neurons in rats. *Acta Physiol.* **236**, (2022).

8.   Lemos, J. C. *et al.* Repeated stress dysregulates κ-opioid receptor signaling in the dorsal

raphe through a p38α MAPK-dependent mechanism. *J. Neurosci. Off. J. Soc. Neurosci.* **32**,

12325–12336 (2012).

9.   Pan, Z. Z., Tershner, S. A. & Fields, H. L. Cellular mechanism for anti-analgesic action of

agonists of the kappa-opioid receptor. *Nature* **389**, 382–385 (1997).

10. Margolis, E. B., Hjelmstad, G. O., Bonci, A. & Fields, H. L. Kappa-opioid agonists directly

inhibit midbrain dopaminergic neurons. *J Neurosci* **23**, 9981–6 (2003).

11. Bals-Kubik, R., Ableitner, A., Herz, A. & Shippenberg, T. S. Neuroanatomical sites

mediating the motivational effects of opioids as mapped by the conditioned place

preference paradigm in rats. *J Pharmacol Exp Ther* **264**, 489–95 (1993).

12. Ehrich, J. M. *et al.* Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK

Activation in VTA Dopamine Neurons. *J Neurosci* **35**, 12917–31 (2015).

13. Graziane, N. M., Polter, A. M., Briand, L. A., Pierce, R. C. & Kauer, J. A. Kappa opioid

receptors regulate stress-induced cocaine seeking and synaptic plasticity. *Neuron* **77**,

942–954 (2013).

14. Vijayraghavan, S., Major, A. J. & Everling, S. Neuromodulation of Prefrontal Cortex in

Non-Human Primates by Dopaminergic Receptors during Rule-Guided Flexible

Behavior and Cognitive Control. *Front. Neural Circuits* **11**, 91 (2017).

15. Narita, M. *et al.* Implication of dopaminergic projection from the ventral tegmental area

to the anterior cingulate cortex in μ-opioid-induced place preference. *Addict. Biol.* **15**,

434–447 (2010).

16. Tichelaar, J. G., Sayalı, C., Helmich, R. C. & Cools, R. Impulse control disorder in

Parkinson's disease is associated with abnormal frontal value signalling. *Brain J. Neurol.*

146, 3676–3689 (2023).

17. Cools, R., Froböse, M., Aarts, E. & Hofmans, L. Dopamine and the motivation of cognitive

control. *Handb. Clin. Neurol.* **163**, 123–143 (2019).

18. Margolis, E. B., Mitchell, J. M., Ishikawa, J., Hjelmstad, G. O. & Fields, H. L. Midbrain

dopamine neurons: projection target determines action potential duration and

dopamine D(2) receptor inhibition. *J Neurosci* **28**, 8908–13 (2008).

19. Margolis, E. B. *et al.* Kappa opioids selectively control dopaminergic neurons projecting

to the prefrontal cortex. *Proc Natl Acad Sci U A* **103**, 2938–42 (2006).

20. Seutin, V., Johnson, S. W. & North, R. A. Effect of dopamine and baclofen on N-methyl-D-

aspartate-induced burst firing in rat ventral tegmental neurons. *Neuroscience* **58**, 201–

206 (1994).

21. Land, B. B. *et al.* The dysphoric component of stress is encoded by activation of the

dynorphin kappa-opioid system. *J Neurosci* **28**, 407–14 (2008).

22. Bruchas, M. R., Land, B. B., Lemos, J. C. & Chavkin, C. CRF1-R activation of the

dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-

like behavior. *PloS One* **4**, e8528 (2009).

23. Van't Veer, A., Yano, J. M., Carroll, F. I., Cohen, B. M. & Carlezon, W. A. Corticotropin-

releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid

receptor antagonist JDTic. *Neuropsychopharmacol. Off. Publ. Am. Coll.*

Neuropsychopharmacol. **37**, 2809–2816 (2012).

24. Wang, B. *et al.* Cocaine experience establishes control of midbrain glutamate and

dopamine by corticotropin-releasing factor: a role in stress-induced relapse to drug

seeking. *J Neurosci* **25**, 5389–96 (2005).

25. Xia, Y.-F., Margolis, E. B. & Hjelmstad, G. O. Substance P inhibits GABAB receptor

signalling in the ventral tegmental area. *J. Physiol.* **588**, 1541–1549 (2010).

26. Margolis, E. B., Hjelmstad, G. O., Fujita, W. & Fields, H. L. Direct bidirectional μ-opioid

control of midbrain dopamine neurons. *J Neurosci* **34**, 14707–16 (2014).

27. Margolis, E. B., Fujita, W., Devi, L. A. & Fields, H. L. Two delta opioid receptor subtypes

are functional in single ventral tegmental area neurons, and can interact with the mu

opioid receptor. *Neuropharmacology* **123**, 420–432 (2017).

28. Cobb-Lewis, D. E., Sansalone, L. & Khaliq, Z. M. Contributions of the Sodium Leak

Channel NALCN to Pacemaking of Medial Ventral Tegmental Area and Substantia Nigra

Dopaminergic Neurons. *J. Neurosci. Off. J. Soc. Neurosci.* **43**, 6841–6853 (2023).

29. Khaliq, Z. M. & Bean, B. P. Pacemaking in dopaminergic ventral tegmental area neurons:

depolarizing drive from background and voltage-dependent sodium conductances. *J.*

Neurosci. Off. J. Soc. Neurosci. **30**, 7401–7413 (2010).

30. Philippart, F. & Khaliq, Z. M. Gi/o protein-coupled receptors in dopamine neurons

inhibit the sodium leak channel NALCN. *eLife* **7**, e40984 (2018).

31. Ingram, S. L. & Williams, J. T. Opioid inhibition of Ih via adenylyl cyclase. *Neuron* **13**,

179–186 (1994).

32. Pan, Z. Z. κ-Opioid receptor-mediated enhancement of the hyperpolarization-activated

current (Ih) through mobilization of intracellular calcium in rat nucleus raphe magnus.

J. Physiol. **548**, 765–775 (2003).

33. Bruchas, M. R. *et al.* Stress-induced p38 mitogen-activated protein kinase activation

mediates kappa-opioid-dependent dysphoria. *J Neurosci* **27**, 11614–23 (2007).

34. Morales, M. & Margolis, E. B. Ventral tegmental area: cellular heterogeneity,

connectivity and behaviour. *Nat Rev Neurosci* (2017) doi:10.1038/nrn.2016.165.

35. Vranjkovic, O. *et al.* Enhanced CRFR1-Dependent Regulation of a Ventral Tegmental

Area to Prelimbic Cortex Projection Establishes Susceptibility to Stress-Induced

Cocaine Seeking. *J. Neurosci. Off. J. Soc. Neurosci.* **38**, 10657–10671 (2018).

36. Deutch, A. Y. *et al.* Stress selectively increases fos protein in dopamine neurons

innervating the prefrontal cortex. *Cereb. Cortex N. Y. N 1991* **1**, 273–292 (1991).

37. Abraham, A. D., Casello, S. M., Land, B. B. & Chavkin, C. Optogenetic stimulation of

dynorphinergic neurons within the dorsal raphe activate kappa opioid receptors in the

ventral tegmental area and ablation of dorsal raphe prodynorphin or kappa receptors

in dopamine neurons blocks stress potentiation of cocaine reward. *Addict. Neurosci.* **1**,

100005 (2022).

38. Sheynikhovich, D., Otani, S., Bai, J. & Arleo, A. Long-term memory, synaptic plasticity and

dopamine in rodent medial prefrontal cortex: Role in executive functions. *Front. Behav.*

Neurosci. **16**, 1068271 (2023).

39. Durstewitz, D. & Seamans, J. K. The dual-state theory of prefrontal cortex dopamine

function with relevance to catechol-o-methyltransferase genotypes and schizophrenia.

Biol. Psychiatry **64**, 739–749 (2008).

40. Robinson, S. E. & Sohal, V. S. Dopamine D2 Receptors Modulate Pyramidal Neurons in

Mouse Medial Prefrontal Cortex through a Stimulatory G-Protein Pathway. *J. Neurosci.*

Off. J. Soc. Neurosci. **37**, 10063–10073 (2017).

41. Soden, M. E. *et al.* Distinct Encoding of Reward and Aversion by Peptidergic BNST

Inputs to the VTA. *Front. Neural Circuits* **16**, 918839 (2022).

42. Grieder, T. E. *et al.* VTA CRF neurons mediate the aversive effects of nicotine

withdrawal and promote intake escalation. *Nat. Neurosci.* **17**, 1751–1758 (2014).

43. Van Pett, K. *et al.* Distribution of mRNAs encoding CRF receptors in brain and pituitary

of rat and mouse. *J. Comp. Neurol.* **428**, 191–212 (2000).

44. Wang, H.-L. & Morales, M. Corticotropin-releasing factor binding protein within the

ventral tegmental area is expressed in a subset of dopaminergic neurons. *J. Comp.*

Neurol. **509**, 302–318 (2008).

45. McFarland, K. & Kalivas, P. W. The circuitry mediating cocaine-induced reinstatement of

drug-seeking behavior. *J. Neurosci. Off. J. Soc. Neurosci.* **21**, 8655–8663 (2001).

46. Combe, C. L. & Gasparini, S. Ih from synapses to networks: HCN channel functions and

modulation in neurons. *Prog. Biophys. Mol. Biol.* **166**, 119–132 (2021).

47. Monteggia, L. M., Eisch, A. J., Tang, M. D., Kaczmarek, L. K. & Nestler, E. J. Cloning and

localization of the hyperpolarization-activated cyclic nucleotide-gated channel family in

rat brain. *Mol. Brain Res.* **81**, 129–139 (2000).

48. Mu, L. *et al.* cAMP-mediated upregulation of HCN channels in VTA dopamine neurons

promotes cocaine reinforcement. *Mol. Psychiatry* **28**, 3930–3942 (2023).

49. Mistrík, P. *et al.* The Murine HCN3 Gene Encodes a Hyperpolarization-activated Cation

Channel with Slow Kinetics and Unique Response to Cyclic Nucleotides. *J. Biol. Chem.*

280, 27056–27061 (2005).

50. Cao, J.-L. *et al.* Mesolimbic dopamine neurons in the brain reward circuit mediate

susceptibility to social defeat and antidepressant action. *J. Neurosci. Off. J. Soc. Neurosci.*

30, 16453–16458 (2010).

51. Cai, M. *et al.* HCN channel inhibitor induces ketamine-like rapid and sustained

antidepressant effects in chronic social defeat stress model. *Neurobiol. Stress* **26**,

100565 (2023).

52. Teichman, E. M. *et al.* Design and validation of novel brain-penetrant HCN channel

inhibitors to ameliorate social stress-induced susceptible phenotype. *Mol. Psychiatry*

(2025) doi:10.1038/s41380-025-02972-8.

Table 1 – Assumption testing and statistical comparisons for summary data

Experiment	Figure	# Neurons; # Outliers; # Extreme outliers	Shapiro-Wilk test of Normality Statistic; p val	Test for Homogeneity of Variances Statistic; p val (Test used)	Parametric test Statistic; p val (Test used)	Non-parametric test Statistic and/or p val (Test used)
U69,593 response (mV), acute stress vs sham	1d	67; 3; 0	0.9; 0.00008	7.5; 0.008 (Levene's)	n/a	0.02 (Permutation, mean)
U69,593 response in BaCl$_2$ vs acute stress	1d,e	49; 4; 0	0.9; 0.0007	3.0; 0.09 (Levene's)	n/a	0.04 (Permutation, SD)
Quinpirole response (mV), acute stress vs sham	1f	27; 2; 1	1.0; 0.6	1.4; 0.2 (Levene's)	0.02; 0.9 (one way ANOVA)	n/a
U69.593 response naïve vs after CRF	1e, 2a	78; 2; 0	1.0; 0.02	0.9; 0.4 (Levene's)	n/a	0.00004
U69,593, first application vs second application	2b, left	6; 0; 0	0.9; 0.6	0.02; 0.9	0.0003; 1.0 (paired t-test)	
U69,593 responses pre- vs post- CRF	2b, right	10; 0; 0	1.0; 0.7	2.0; 0.2	-2.0; 0.08 (paired t-test)	
U69,593, first application vs second application	2c	6; 0; 0			5.1; 0.007 (Pearson's product moment correlation, coeff = 0.9)	
U69,593 responses pre- vs post- CRF, in neurons with a post-CRF U69,593 induced depolarization	Subset in 2c	5			-3.7; 0.03 (Pearson's product moment correlation, coeff = -0.9)	
U69,593 responses differ by projection target	3	48; 6; 3	0.8; 0.0000001	1.4; 0.3	n/a	12.4; 0.006 (Kruskal-Wallis rank sum test) Pairwise comparisons (p adjustment method BH): dmPFC-BLA: 0.05 dmPFC-NAc: 0.05 dmPFC-vmPFC: 0.03 BLA-NAc: 0.4 BLA-vmPFC: 0.4 NAc-vmPFC: 0.2
U69,593 after CRF vs after CRF with GDP-β-s	4a	34; 1; 0	0.9; 0.007	4.4; 0.05	n/a	0.01 (Permutation, SD)
U69,593 after CRF vs after CRF with ZD7288	4a	39; 2; 1	0.9; 0.06	2.5; 0.1	0.7; 0.4 (one way ANOVA)	
U69,593 after CRF vs after CRF with TTX, DNQX, gabazine	4a	47; 4; 0	0.9; 0.005	1.2; 0.3	n/a	0.3 (Permutation, mean)
U69,593 after CRF vs after CRF with BaCl$_2$	4a	38; 1; 0	0.9; 0.01	2.5; 0.1	n/a	0.5 (Permutation, mean)
U69,593 after CRF vs after CRF with CdCl$_2$	4a	33; 1; 0	0.9; 0.007	0.01; 0.9	n/a	0.6 (Permutation, mean)
U69,593 after CRF vs after CRF with NMDG	4a	31; 1; 0	0.9; 0.01	1.1; 0.3	n/a	0.2 (Permutation, mean)
U69,593 after CRF vs after CRF with SB203580 (only during U69,593)	4a	36; 1; 0	0.9; 0.00008	7.5; 0.008	n/a	0.4 (Permutation, mean)
I_h magnitude after U69,593, with vs without CRF pretreatment	4b	18; 2; 0	0.9; 0.02	1.7; 0.2	n/a	0.3 (Permutation, mean)
U69,593 after CRF vs after CRF with SB203580 (applied	4a,c	34; 2; 0	1.0; 0.2	0.0007; 1.0	3.8; 0.06	

during CRF and U69,593)						
Intra-VTA U69,593 place conditioning, sham- vs shock-treated rats	5b	20 rats; 0; 0	Base-sham: 1.0; 0.8 Base-shock: 0.9; 0.6 Sham-test: 0.9; 0.5 Shock-test: 0.9; 0.4	Sham: 0.9; 0.4 Shock: 3.5; 0.08	Pretreatment-U69,593 interaction: 9.0; 0.008 (Two way mixed measures ANOVA) Pairwise comparisons: Sham, Base vs test: 0.0004 Shock, Base vs test: 0.6 (Bonferroni corrected)	
Baseline Ri in neurons from stress vs sham animals	Supp 2	139; 0; 0	1.0; 0.01	0.5; 0.5		0.2 (Permutation, mean)
Spontaneous AP duration in neurons from stress vs sham animals	Supp 2	81; 1; 0	0.9; 0.00002	0.9; 0.3		0.8 (Permutation, mean)
Spontaneous AP threshold in neurons from stress vs sham animals	Supp 2	81; 0; 0	1.0; 0.8	0.9; 0.3	9.5; 0.003 (one way ANOVA)	
Spontaneous AP peak in neurons from stress vs sham animals	Supp 2	81; 1; 0	1.0; 0.09	1.5; 0.2	0.2; 0.7 (one way ANOVA)	
I_h magnitude in neurons from stress vs sham animals	Supp 2	129; 17; 10	0.6; <0.000001	0.5; 0.5		0.4 (Permutation, mean)
Baseline spontaneous firing rate in neurons from stress vs sham animals	Supp 2	60; 5; 3	0.8; <0.000001	0.4; 0.5		0.3 (Permutation, mean)
Proportion of spontaneously active neurons from stress vs sham animals						0.9 (two tailed Fisher exact test)
Baseline Ri in neurons from stress animals grouped by U69,593 response type	Supp 3	46; 0; 0	1.0; 0.4	0.2; 0.8	3.2; 0.04 (one way ANOVA) Pairwise comparisons: Inhib-excit: 0.04 Inhib-no resp: 0.2 Excit-no resp: 0.9	
AP duration in neurons from stress animals grouped by U69,593 response type	Supp 3	27; 0; 0	0.9; 0.1	4.4; 0.02		3.1; 0.2 (Kruskal-Wallis rank sum test)
AP threshold in neurons from stress animals grouped by U69,593 response type	Supp 3	27; 0; 0	1.0; 0.4	1.5; 0.2	0.3; 0.7 (one way ANOVA)	
AP peak in neurons from stress animals grouped by U69,593 response type	Supp 3	27; 1; 0	0.9; 0.1	0.6; 0.5	0.8 (one way ANOVA)	

| CORT from recording animals, foot shock vs sham | Supp 6 | 16 rats; 1; 0 | 0.9; 0.2 | 0.09; 0.8 | 0.05 (one way ANOVA) | |

Extended Data Figure 1

a

TH(+) neurons

Change in V_m with U69,593 (mV)

≥10

−5

Foot shock: sham same day 3 days earlier 5 days earlier

b

Change in V_m with U69,593 (mV)

≥ 5.0
2.5
0.0
−2.5
≤−5.0

Ventral   Middle   Dorsal

SNc

A

SNr

P

IPN

←L   M→

Extended Data Figure 2

Extended Data Figure 3

Extended Data Figure 4

a

b

200 pA

500 ms

c

exp fit

d

Baseline   U69,593

Time

CRF   Baseline   U69,593

Time

e

Change in I_h $V_{1/2}$ (mV)

20
10
0
−10
−20
−30

f

Change in I_h $V_{reverse}$ (mV)

−10

−20

g

I_h activation τ (ms)

baseline   U69,593   baseline   U69,593

Extended Data Figure 5

Sham

Bregma -5.52 mm

Bregma -5.76 mm

N = 11

Bregma -6.24 mm

Foot shock

Bregma -5.52 mm

Bregma -5.76 mm

N = 11

Bregma -6.24 mm

Extended Data Figure 6